261 related articles for article (PubMed ID: 34958507)
1. Cutaneous histiocytoses in children.
Fraitag S; Emile JF
Histopathology; 2022 Jan; 80(1):196-215. PubMed ID: 34958507
[TBL] [Abstract][Full Text] [Related]
2. Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations.
Luder CM; Nordmann TM; Ramelyte E; Mühleisen B; Kerl K; Guenova E; Dummer R
J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):926-934. PubMed ID: 29341328
[TBL] [Abstract][Full Text] [Related]
3. Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses.
Mavrogenis AF; Igoumenou VG; Antoniadou T; Megaloikonomos PD; Agrogiannis G; Foukas P; Papageorgiou SG
EFORT Open Rev; 2018 Jun; 3(6):381-390. PubMed ID: 30034819
[TBL] [Abstract][Full Text] [Related]
4. Musculoskeletal imaging features of non-Langerhans cell histiocytoses.
Choraria A; Andrei V; Rajakulasingam R; Saifuddin A
Skeletal Radiol; 2021 Oct; 50(10):1921-1940. PubMed ID: 33787962
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adult xanthogranuloma with a small portion of BRAF
Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
[TBL] [Abstract][Full Text] [Related]
6. Non-Langerhans cell histiocytoses. A new unifying concept.
Zelger BW; Sidoroff A; Orchard G; Cerio R
Am J Dermatopathol; 1996 Oct; 18(5):490-504. PubMed ID: 8902096
[TBL] [Abstract][Full Text] [Related]
7. OCT2 expression in histiocytoses.
Ungureanu IA; Cohen-Aubart F; Héritier S; Fraitag S; Charlotte F; Lequain H; Hélias-Rodzewicz Z; Haroche J; Donadieu J; Emile JF
Virchows Arch; 2023 Jul; 483(1):81-86. PubMed ID: 36754897
[TBL] [Abstract][Full Text] [Related]
8. The non-Langerhans' cell histiocytoses in childhood.
Burgdorf WH; Zelger B
Cutis; 1996 Sep; 58(3):201-7. PubMed ID: 8886534
[TBL] [Abstract][Full Text] [Related]
9. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
10. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
Bonometti A; Ferrario G; Parafioriti A; Giardino D; Simonetti F; Ginori A; Passoni E; Berti E;
J Cutan Pathol; 2021 May; 48(5):637-643. PubMed ID: 33188581
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cell histiocytosis and juvenile xanthogranuloma. Two case reports.
Patrizi A; Neri I; Bianchi F; Guerrini V; Misciali C; Paone G; Burnelli R
Dermatology; 2004; 209(1):57-61. PubMed ID: 15237270
[TBL] [Abstract][Full Text] [Related]
12. Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease.
Conley A; Manjila S; Guan H; Guthikonda M; Kupsky WJ; Mittal S
Neuropathology; 2010 Dec; 30(6):634-47. PubMed ID: 20337948
[TBL] [Abstract][Full Text] [Related]
13. Histiocytosis with mixed cell populations.
Martín JM; Jordá E; Martín-Gorgojo A; Beteta G; Monteagudo C
J Cutan Pathol; 2016 May; 43(5):456-60. PubMed ID: 26968131
[TBL] [Abstract][Full Text] [Related]
14. [Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group].
Adam Z; Szturz P; Pour L; Krejčí M; Zahradová L; Tomíška M; Král Z; Koukalová R; Rehák Z; Mayer J
Vnitr Lek; 2012 Jun; 58(6):455-65. PubMed ID: 22913238
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous non-Langerhans cells histiocytoses as cause of central diabetes insipidus].
Miranda PA; Miranda SM; Bittencourt FV; Machado LJ; Castro LP; Leite VH; Lauria MW; Braga WR; Oliveira AR
Arq Bras Endocrinol Metabol; 2007 Aug; 51(6):1018-22. PubMed ID: 17934672
[TBL] [Abstract][Full Text] [Related]
16. Congenital histiocytosis. A heterogeneous group of diseases, one presenting as so-called congenital self-healing histiocytosis.
Kodet R; Elleder M; De Wolf-Peeters C; Mottl H
Pathol Res Pract; 1991 May; 187(4):458-66. PubMed ID: 1908575
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
Geerlinks AV; Abla O
Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
[TBL] [Abstract][Full Text] [Related]
18. [An overview of histiocytosis].
Tojo A
Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
[TBL] [Abstract][Full Text] [Related]
19. Fetal and neonatal histiocytoses.
Isaacs H
Pediatr Blood Cancer; 2006 Aug; 47(2):123-9. PubMed ID: 16416419
[TBL] [Abstract][Full Text] [Related]
20. Nosology and Pathology of Langerhans Cell Histiocytosis.
Picarsic J; Jaffe R
Hematol Oncol Clin North Am; 2015 Oct; 29(5):799-823. PubMed ID: 26461144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
